natgillin/translations-raw huggingface dataset:
The compound or salt for use according to claim 23, wherein said cancer is selected from prostate cancer, renal cancer, hepatic cancer, gastric cancer, thyroid cancer, glioblastoma, Karposi's sarcoma, Castleman's disease, melanoma, cutaneous T-cell lymphoma (CTCL), cutaneous Bell lymphoma, Sezary syndrome, mycosis fungoides, acute lymphoblastic leukemia, and colorectal cancer. 
Spoj ili sol za upotrebu prema patentnom zahtjevu 23, naznačen time da je navedeni tumor izabran od tumora prostate, tumora bubrega, tumora jetre, tumora želuca, tumora štitnjače, glioblastoma, Karposijevog sarkojema, Castlemanove bolesti, melanoma, kožnog limfoma 'T-stanica (CTCL), kožnog Bell limfoma, Sezaryovog sindroma, mycosis fungoides, akutne limfoblastične leukemije, 1 tumora debelog crijeva.
A composite material comprising one or more fillers and a polymerizable resin base, wherein said one or more fillers comprise at least one filler ingredient, said at least one filler ingredient being present in a metastable first phase and being able to undergo a martensitic transformation to a stable second phase, a volume ratio between said stable second phase and said metastable first phase of said at least one filler ingredient being at least 1.005, 
Kompozitni materijal koji sadrži jedan ili više punila i bazu za smolu koja polimerizira, naznačen time da rečeno jedno ili više punila sadrže jedan ili više materijala za punila, a rečeni materijal(i) za punilo je prisutan u metastabilnoj prvoj fazi koja može proći kroz martenzitsku transformaciju u drugu fazu, a omjer volumena između rečene stabilne druge faze i rečene metastabilne prve faze rečenog materijala za punjenje je najmanje 1.005.
The amount of each active which is required to achieve a therapeutic effect will, of course, vary with the particular active, the route of administration, the subject under treatment, and the particular disorder or disease being treated. 
Količina svake djelatne tvari potrebne za postizanje terapijskog učinka ovisit će, naravno, o konkretnoj djelatnoj tvari, ruti primjene, bolesniku koji se liječi 1 konkretnom poremećaju ili bolesti koja se liječi.
The method according to any of the claims 1 to 3, wherein the disease or disorder is heart failure, cachexia, acute coronary syndrome, chronic stress syndrome, cushing's syndrome, metabolic syndrome or hypercortisolemia. 
Spoj ili njegova farmaceutski prihvatljiva sol za uporabu prema zahtjevu 1, naznačen time, što bolest ili poremećaj je Cushingov sindrom.
the Tmax is less than 2 hours, preferably less than 1 hour or less than 0.5 hours, or 
T max je manji od 2 sata, poželjno manje od 1 sata ili manje od 0,5 sati, ili
In one embodiment, X is selected from a monocyclic heteroaryl having 5 ring atoms selected from C, O, S and N provided the total number of ring heteroatoms is less than or equal to four and where no more than one of the total number of heteroatoms is oxygen or sulfur, and a monocyclic aromatic ring having 6 atoms selected from C and N provided that not more than 3 ring atoms are N, and where said ring may be optionally and independently substituted with up to two groups selected from C1-C4 alkyl, cycloalkyl, cycloalkyloxy, C1-C4 alkoxy, CF3, carboxy, alkoxyalkyl, C1-C4 cycloalkylalkoxy, amino, alkylamino, dialkylamino, amido, alkylamido, dialkylamido, thioalkyl, halogen, cyano, alkylsulfonyl and nitro. 
Spoj prema zahtjevu 4, naznačen time da je X opcionalno supstituirani prsten monocikličkog arila koji u prstenu ima pet atoma izabranih između C, O, S 1N, s time da je ukupni broj heteroatoma u prstenu manji od ili jednak četiri 1 da je najviše jedan od heteroatoma u prstenu kisik ili sumpor, naznačen time da je prsten heteroarila opcionalno i nezavisno supstituiran s najviše dva supstituenta izabrana iz skupine koju sačinjavaju C;-C4 alkil, C2C4 cikloalkil, C2-Cg cikloalkiloksi, Ci-C, alkoksi, CF2, karboksi, alkoksialkil, C,-Ca cikloalkilalkoksi, amino, alkilamino, dialkilamino, amido, alkilamido, dialkilamido, tioalkil, halogen, cijano, alkilsulfonil i nitro.
R is selected from the group consisting of 
R se bira iz skupine koju čine
The metal substrate of claim 13, wherein the electroplated metal layer is selected from the group consisting of nickel, nickel-phosphorus, copper, brass, gold, silver, and platinum, and optionally wherein the metal substrate is selected from a coinage metal or alloy. 
Metalna podloga u skladu s patentnim zahtjevom 8, naznačen time što se galvanizirani metalni sloj bira iz skupine koju čine nikal, niklo-fosfor, bakar, mjed, zlato, srebro, te platina.
A pharmaceutical composition according to any one of paras. 1 to 26, further comprising: aqueous saline solution or aqueous glucose solution. 
Farmaceutski sastav prema zahtjevu 11 ili 12, naznačen time, da nadalje sadrži: vodenu solnu otopinu ili vodenu otopinu glukoze.
This mixture is treated with a suitable base to complete the epimerization to produce the cis-isomer (21). Suitable bases include, for example, triethylamine, 1,5-diazabicyclo[4,3,0]non-5-ene, 1,4-diazabicyclo[2,2,2]octane, and 1,8-diazabicyclo[5,4,0]undec-7-ene. 
Postupak u skladu s patentnim zahtjevom 57, naznačen time što navedenu bazu se bira iz skupine koju čine trietilamin; 1,5-diazabiciklo[4.3.O0]non-5-en; 1,4-diazabiciklo[2.2.2]oktan; i 1,8-diazabiciklo[5.4.0]lundec-7-en.
It comprises a plunger 2 which is arranged in a cylinder 4. 
Ona obuhvaća klipnjaču 2 koja se nalazi u cilindru 4.
This is denoted overall by 11. 
Ta cijela varijanta je označena s 11.
Preferred concentration ranges of the compounds of the medium to be used in the process of the invention are as follows: 
Preporučeni koncentracijski rasponi sastojaka medija koji se koristi u procesu predstavljenom izumom su kako slijedi:
This background art is disclosed in EP-A-1 510 161 which, pursuant to Article 54(3) and (4) EPC, is comprised in the state of the art as it has an older priority date, but has been published after the priority date of the invention as claimed herein. 
Ta pozadina je izložena u EP-A-1 510 161 i koja je, prema članku 54(3) i (4) EPC, sadržana u stanju tehnike budući da ima raniji datum prvenstva, ali je objavljena nakon datuma prvenstva ovog izuma.
heating the solution resulting from step (vi) to a temperature of about 50 to 100° C. in about 0.15 to 30 minutes; 
(1i) zagrijavanje otopine dobivene u koraku (1) do temperature od 50 do 100%C kroz 0.15 do 30 minuta;
Inclined plane test: characterization of the motor deficit 
Broj objave europskog patenta:
A method for treatment or prophylaxis of heart failure, pulmonary hypertension, chronic obstructive pulmonary disease, asthma, diabetic nephropathy, fibrotic disorders of the heart and dermatological fibroses comprising administering to a human an effective amount of the compound according to claim 6 . 
Lijek prema zahtjevu 15 ili 16 naznačen time da je za uporabu za liječenje i/ili profilaksu zatajenja srca, plućne hipertenzije, kronične opstruktivne plućne bolesti, astme, zatajenja bubrega, nefropatije, fibroznih poremećaja unutarnjih organa, dermatoloških fibroza.
is substituted phenyl or substituted pyridinyl, wherein substituted phenyl and substituted pyridinyl are substituted with R3, R4 and R5; 
je supstituirani fenil ili supstituirani piridinil, pri čemu su supstituirani fenil i supstituirani piridinil supstituirani s R3, R4 i R5;
In certain embodiments, the buffer is succinate at a final concentration of 1 mM to 10 mM and pH 5.8 to 6.0. 
Formulacija u skladu s patentnim zahtjevom 20, naznačena time što je pufer sukcinatni, u konačnoj koncentraciji od 5 mM.
The method of claim 1, wherein the steroidal anti-inflammatory agent is a corticosteroid or a pharmaceutically acceptable salt or solvate thereof. 
Farmaceutski pripravak iz patentnog zahtjeva 5, naznačen time, da je steroidno protu-upalno sredstvo kortikosteroid ili njegova farmaceutski prihvatljiva sol ili solvat.
control the apparatuses in the chain. The system according to claim 1, wherein the primary unit (5A, 5B, 5C) is operable to receive energy from a power source and data signal from a data source. 
Sustav u skladu s patentnim zahtjevom 1, naznačen time što se primarnu jedinicu (SA, 5B, 5C) može upotrijebiti za prijem energije iz izvora napajanja i podatkovnog signala iz izvora podataka.
C is a cleavable group; subscripts a and b are independently 0 or 1; subscript m is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; and 
C je grupa koja se može presjeći; indeksi a 1 b su nezavisno 0 ili I; indeks m je 1, 2, 3, 4, 5, 6, 7, 8, 9, ili 10; 1
A compound of claim 1 having a structure according to formula (Ia): or a salt or polymorph thereof wherein X1 is absent and R1 is selected from hydrogen, alkyl, lower alkyl-sulfonyl, aryl, C3-C12 cycloalkyl or heterocyclyl, wherein aryl or heterocyclyl are each optionally substituted at one or more positions by halogen, aminosulfonyl or alkyl optionally substituted at one or more positions by halogen; R3 is -C(O)-NH-Za(R10): X3 is absent or lower alkylidene; Z3 is absent, -SO2- or alkyl (wherein alkyl is optionally substituted at one or more positions by halogen, hydroxy or carbonylalkoxy); R10 is hydrogen or heterocyclyl, wherein heterocyclyl is optionally substituted by one or more carbonylaikoxy-, the dashed line between position 8 and X4R4 is present, X4 is absent and R4 is CH-aryl or CH-heterocyclyl, wherein aryl or heterocyclyl are each optionally substituted at one or more positions by lower alkoxy or halogen. or a salt or pdymorph thereof 
BL Raa bm, (la) ili njegova sol ili polimorf pri čemu X, je odsutan i R; je odabran od vodika, alkila, nižeg alkil-sulfonila, arila, C3- C,> cikloalkila ili heterociklila, pri čemu aril ili heterociklil su svaki proizvoljno supstituirani u jednom ili više položaja sa halogenom, aminosulfonilom ili alkilom proizvoljno supstituiranim u jednom ili više položaja sa halogenom; R: je -C(O)-NH-Za(R:o): X; je odsutan ili niži alkiliden; Z; je odsutan, ili alkil (pri čemu je alkil proizvoljno supstituiran u jednom ili više položaja sa halogenom, hidroksi ili karbonilalkoksi); R;g je vodik ili heterociklil, pri čemu heterociklil je proizvoljno supstituiran sa jednim ili više karbonilalkoksi-, prisutna je
The method according to claim 1 wherein the disubstituted azodicarboxylate is chosen from dimethylazodicarboxylate, diethyl azodicarboxylate, diisopropylazodicarboxylate, di-tert-butylazodicarboxylate and 1,1′-(azodicarbonyl)dipiperidine. 
Postupak prema bilo kojem od prethodnih patentnih zahtjeva naznačen time da je disupstituirani azodikarboksilat izabran iz = dimetilazodikarboksilata, = dietilazodikarboksilata, = diizopropilazodikarboksilata, = di-tertbutilazodikarboksilata i 1,1'-(azodikarbonil)dipiperidina.
The method according to one of the preceding variants, wherein the step of measuring at least one further physical quantity comprises measuring vibrations of the anchor, and/or measuring a force exerted onto the anchor through an anchor rode, and/or measuring an underwater pressure at a location of the anchor. 
4. Postupak prema jednom od prethodnih patentnih zahtjeva, pri čemu korak mjerenja najmanje jedne daljnje fizikalne veličine obuhvaća mjerenje vibracija sidra i/ili mjerenje sile koja se vrši na sidro preko sidrenog lanca (3) iili mjerenje podvodnog tlaka na mjestu sidra.
Examples of muscarinic receptor antagonists include atropine, hyoscine, glycopyrrolate (glycopyrronium), ipratropium, tiotropium, oxitropium, pirenzepine, telenzepine, aclidinium and umeclidinium. 
Pripravak prema zahtjevu 1 ili 2, pri čemu je antagonist muskarinskog receptora (b) atropin, hioscin, glikopirolat, ipratropij, tiotropij, oksitropij, pirenzepin, telenzepin, aklinidij ili umeklidinij.
A ball launcher according to one of the preceding claims 7-9, wherein said airflow controller (17) is adapted to control the position of the ball shuttle (9) and/or the power of the airflow generator (5) in response to the determined ball speed. 
Uređaj za lansiranje kuglice sukladno bilo kojem od prethodnih patentnih zahtjeva, naznačen time, da je 7-9, pri čemu je navedeni upravljač (17) protoka zraka prilagođen da regulira položaj prijenosnika (9) kuglice i/ili snagu generatora (5) protoka zraka kao odgovor na utvrđenu brzinu kuglice.
The panel as claimed in claim 1 or 2, wherein material strips (2, 2', 2",...) extend over one and the same neighboring core element (1, 1', 1 ",...) and along both panel surfaces. 
Ploča u skladu s patentnim zahtjevom 1 ili 2, naznačena time što se trake od materijala (2, 2/, 2",...) prostiru preko samo jednog i istog susjednog središnjeg elementa (1, 1", 1",...)
A composition for use according to claim 1-8 wherein the patient is over 65 years of age. 
Pripravak naznačen time da je za uporabu prema zahtjevu 8 u postupku koji sadrži:
A pharmaceutical composition of claim 17, further comprising one or more additional active agents. 
Farmaceutski sastav prema zahtjevu 18 ili 19, naznačen time, da nadalje obuhvaća jedno ili više dodatnih djelotvornih sredstava.
A Plastoferrite plate (model M201.1, Maurer magnetics AG, CH-8627 Grüningen) was magnetised in a direction perpendicular to the surface and then engraved on a computer-controlled mechanical engraving station with a geometrical design (two pyramids; see FIG. 3 a). 
Ploča izrađena od Plastofenita (model M201.1, Maurer magnetics AG, CH-8627 Gruningen) se magnetizira u smjeru okomito na površinu, nakon čega se na računalno nadziranoj mehaničkoj postaji za graviranje na ploču ugravira geometrijski uzorak (dvije piramide; vidi Sliku 3a).
The single immunoglobulin variable domain antibody of claim 3, wherein the PEG is linked via a cysteine or lysine residue; or wherein the PEG is about 10 to about 50 kD; or wherein the single immunoglobulin variable domain antibody has a hydrodynamic size of at least about 24 kD; or wherein the single immunoglobulin variable domain antibody has a hydrodynamic size of at least about 200 kD; or wherein the single immunoglobulin variable domain antibody has a ta half-life of about 15 seconds to about 12 hours; or wherein the single immunoglobulin variable domain antibody has a tB half-life of about 12 hours to about 744 hours. 
Antitijelo koje sadrži jednu imunoglobulinsku varijabilnu domenu iz zahtjeva 3, naznačeno time, što je PEG vezan preko cisteinske ili lizinske rezidue; ili gdje PEG ima oko 10 do oko 50 kD; ili gdje antitijelo koje sadrži jednu imunoglobulinsku varijabilnu domenu ima hidrodinamičku veličinu od najmanje oko 24 kDa; ili gdje antitijelo koje sadrži jednu imunoglobulinsku varijabilnu domenu ima hidrodinamičku veličinu od najmanje oko 200 kDa; ili gdje antitijelo koje sadrži jednu imunoglobulinsku varijabilnu domenu ima ta-poluživot od oko 15 sekundi do oko 12 sati; ili gdje antitijelo koje sadrži jednu imunoglobulinsku varijabilnu domenu ima tB-poluživot od oko 12 sati do oko 744 sata.
It is possible to provide the corresponding bonding spots and/or bonding areas unevenly distributed in circumferential direction. 
Moguće je staviti odgovarajuće točke spajanja i/ili područja spajanja tako da su nejednoliko raspoređeni u obodnom smjeru.
According to another embodiment of the present invention, the cPCC comprises aggregates having a weight median particle diameter d50 value from 0.2 to 25.0 µm, more preferably from 0.3 to 10.0 µm and most preferably from 0.4 to 5.0 µm, measured according to the sedimentation method. 
Upotreba u skladu s patentnim zahtjevom 1 ili 2, naznačena time što cPCC sadrži agregate s vrijednošću težinski usrednjenog promjera čestica dsg od 0,2 do 25,0 um, poželjnije od 0,3 do 10,0 um, a najpoželjnije od 0,4 do 5,0 um, što je izmjereno postupkom taloženja.
The method of claim 91, wherein the peptide has an amino acid sequence comprising SEQ ID NO:69. 
Himerni peptid sukladno zahtjevu 1, naznačen time što sadrži SEQ ID NO:69.
and R10 are independently hydrogen, optionally substituted linear or branched C1-C10 alkyl, optionally substituted linear or branched C2-C10 alkenyl, optionally substituted linear or branched C2-C10 alkynyl, optionally substituted C4-C8 cyclyl, optionally substituted C3-C8 heterocyclyl, or R9 and R10 together with the carbon they are attached to form an optionally substituted 3-8 membered cyclyl or heterocyclyl, or 
i R10su neovisno vodik, opcijski supstituirani linearni ili razgranati C1-C10alkil, opcijski supstituirani linearni ili razgranati C2-C10alkenil, opcijski supstituirani linearni ili razgranati C2-C10alkinil, opcijski supstituirani C4-C8ciklil, opcijski supstituirani C3-C8heterociklil, pod uvjetom da najmanje jedan od R9 i R10 nije vodik, ili R9 i R10zajedno s ugljikom za koji su vezani obrazuju opcijski supstituirani
reacting trifluoroacetyl glatiramer acetate with aqueous piperidine to form a solution of glatiramer acetate; and 
dovođenje u reakciju trifluoracetil glatiramer acetata s vodenastim piperidinom, da bi se formirala otopina vodenastog glatiramer acetata; i
is selected from the group consisting of C1-6 alkyl, substituted C1-6 alkyl, C2-6 alkenyl, substituted C2-6 alkenyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycle, substituted heterocycle, cycloalkyl, substituted cycloalkyl, cycloalkenyl and substituted cycloalkenyl; is hydrogen; 
je odabran iz skupine koju čine C1-6-alkil, supstituirani C1-6-alkil, C2-6-alkenil, supstituirani C2-6-alkenil, aril, supstituirani aril, heteroaril, supstituirani heteroaril, heterocikl, supstituirani heterocikl, cikloalkil, supstituirani cikloalkil, cikloalkenil i supstituirani cikloalkenil; je vodik;
converting a compound of formula [48] to a compound of formula [49] wherein R1 and R6 are defined above; 
prevođenju spoja formule [48] u spoj formule [49] [image], gdje su R1 i R6 definirani gore;
TLC analysis (silica, ethyl acetate) showed that no (+)-B-DHTBZ remained in the crude product. 
TLC analiza (silicij, etil acetat) pokazuje da u sirovom produktu nije preostalo (+)-B-DHTBZ.
When as shown the latching groove 38 overlies the latch keys 16 and the latter occupy their latching position to which they are urged by the springs 36, the shoulders 39 a,b defined by protuberances 41 and the surfaces 20 engage to permit the transfer of longitudinally acting forces between the latch sub 14 and the jar mandrel 13 . 
Kada zabravljujući žlijeb 38, kako se vidi, prevladava zasun 16 i isti zahvaća zabravljujući položaj, koji je posljedica djelovanja kompresijske opruge 36, ramena 392, 39b definirana ispupčenjima 41 i površinama 20 su zahvaćena tako da dozvoljavaju prenošenje uzdužnih djelujućih sila između elementa 14 zasuna i vretena 13 udaraca.
In another aspect the invention provides a combination of Tesofensine or a pharmaceutically acceptable salt thereof, and Metoprolol, or a pharmaceutically acceptable salt thereof, the treatment, prevention or alleviation of obesity, or an obesity associated disorder, and for treatment, prevention or alleviation of the cardiovascular side effects of Tesofensine. 
Kombinacija tesofenzina, ili njegove farmaceutski prihvatljive soli i metoprolola, ili njegove farmaceutski prihvatljive soli za uporabu prema zahtjevu 1, naznačena time što je poremećaj povezan s pretilosti dijabetes tipa 2.
The isolated antibody according to claim 1 wherein the heavy chain comprises SEQ ID NO:21 and the light chain comprises SEQ ID NO:22. An isolated antibody which specifically binds human CD38 (SEQ ID NO:1) and cynomolgus CD38 (SEQ ID NO:2) comprising: 
Izolirano protutijelo koje specifično veže ljudski CD38 (SEQ ID NO: 1) 1 makaki CD38 (SEQ ID NO:2) koje sadrži: a) = varijabilnu regiju teškog lanca koja sadrži SEQ ID NO:9; 1 b) varijabilnu regiju lakog lanca koja sadrži SEQ ID NO:10.
The long term storage stable bendamustine-containing composition of any of the previous claims, wherein the antioxidant is selected from the group consisting of thioglycerol, monothioglycerol, lipoic acid, propyl gallate, methionine, cysteine, metabisulfites, sodium formaldehyde sulfoxylate, phenol-containing aromatic and aliphatic compounds and dihydrolipoic acid. 
Stabilan pri dugotrajnom skladištenju, nevodeni tekući pripravak s bendamustinom prema bilo kojem od prethodnih zahtjeva, naznačen time, da je antioksidans odabran 1z skupine koju čine tioglicerol, monotioglicerol, lipoinska kiselina, propil galat, metionin, cistein, metabisulfiti, natrijev formaldehid sulfoksilat, aromatski i alifatski spojevi s fenolom i dihidrolipoinska kiselina.
The composition according to claim 1, wherein component (A) is 3difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-difluoromethylidene-benzonorbornene-5-yl) amide and component (B2) is selected from the group consisting of difenoconazole, ipconazole, prothioconazole, tebuconazole, propiconazole, cyproconazole, and epoxiconazole. 
Spoj prema zahtjevu 1, naznačen time, da sadrži kao komponentu (A) spoj (9-difluorometiliden-benzonorbornen-5-iljamid 3-difluorometil-1-metil-1H-pirazol-4-karboksilne kiseline, te kao komponentu (B) fenpropidin.
A process for the preparation of a compound of claim 1, which comprises: for a compound of Formula I wherein R2 is NRbRc, reacting a corresponding compound of formula II with a compound having the formula HNRbRc in the presence of a coupling reagent; or 
Postupak dobivanja spoja u skladu s patentnim zahtjevom 1, naznačen time što se sastoji u: (a) za spoj Formule I, gdje je R* NR*R", reakciji odgovarajućeg spoja Formule II
is selected from the group consisting of: 
R* je odabran iz skupine koju čine:
moving the ejector from the retracted configuration toward the expanded configuration to move the contents of the respective oven of the plurality of ovens out of the respective oven without the contents being touched by a human. 
pomicanje uređaja za izbacivanje (246) iz uvučene konfiguracije prema rastegnutoj konfiguraciji, u svrhu pomicanja sadržina štednjaka izvan štednjaka, bez doticaja ljudskih ruku sa sadržajem.
the process comprising: reacting a compound of formula (3) wherein u, v, R1, and R2 are as described for formula (7); and LG is a leaving group; 
LK gdje u, v, R',i R? su kako je opisano za formulu (7); i LG je odlazeća skupina; sa spojem formule (4) oo bA ', Å A ša o ia
vii) any hydrophobic residues in the up to three amino acids at the N or C terminus of the native sequence of the polypeptide, which are not comprised in a T cell epitope, deleted; and/or viii) any two consecutive amino acids comprising the sequence Asp-Gly in the up to four amino acids at the N or C terminus of the native sequence of the polypeptide, which are not comprised in a T cell epitope, deleted. 
svaki hidrofobni ostaci sve do tri aminokiseline kod N ili C krajeve od izvorne sekvence peptida, koji nisu sadržani u T stanici epitopa brišu se, i / ili vi) bilo koje dvije uzastopne aminokiseline koje sadrže sekvencu Asp-u Gly sve do četiri aminokiseline kod N ili C krajeva od izvorne sekvence peptida, koji nisu sadržani u T stanici epitopa brišu se.
Process according to claim 7, wherein said first oxidizing system is 30% H2O2/Fe(II) salt and said second oxidizing system is selected from the group consisting of acetic acid, CrO3, and MnO2. 
Postupak u skladu s patentnim zahtjevom 7, naznačen time što je navedeni prvi oksidacijski sustav 30% H202/Fe(1]) sol, a navedeni drugi oksidacijski sustav se bira iz skupine koju čine octena kiselina, CrO5 1 MnO».
The composition according to claim 1, wherein the DPP-IV inhibitor has an IC50 of less than 1 µM. 
Pripravak u skladu sa zahtjevom 1, naznačen time, da DPP-IV inhibitor ima IC50 manji od 1 uM.
Use according to any of the preceding articles, wherein the medicament comprises from about 0.02% to 100% w/w such as, e.g. from about 0.1 % to about 95% w/w, from about 1% to about 95% w/w, from about 5% to about 95% w/w, from about 10% to about 90% w/w, from about 15% to about 90% w/w of the one or more oligomers of lactic acid or the oligomeric product. 
Jedan ili više oligomera mliječne kiseline za uporabu prema bilo kojem prethodnom patentnom zahtjevu, pri čemu je jedan ili više oligomera mliječne kiseline sadržan u pripravku koji sadrži od 0.02% do 100% w/w, od 0.1% do 95% w/w, od 1% do 96% w/w, od 5% do 95% w/w, od 10% do 90% w/w, od 15% do 90% w/w jednog ili više oligomera mliječne kiseline.